Dachaigh › Cancer briste triple-negative › California › San Francisco
Sgrùdaidhean clionaigeach Cancer briste triple-negative ann an San Francisco, CA
Tha aon sgrùdadh airson Cancer briste triple-negative a’ lorg phàirtichean aig làrach ann no faisg air San Francisco. Fosglaidh e gus faicinn cò as urrainn pàirt a ghabhail agus mar a chuireas tu fios air an sgioba.
Teacsa sgrùdaidh oifigeil (Beurla)
A’ fastadh airson sgrùdadh an seo? Seall e aig mullach na duilleige seo — $99 airson 30 latha →
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
A’ fastadhÌre 3
- UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0016), San Francisco
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
A’ fastadhÌre 3
- Kaiser Permanente - San Francisco ( Site 0080), San Francisco
Intratumoral N17350 in Advanced Solid Tumors
A’ fastadhÌre 1/2
- University of California, San Francisco, San Francisco
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
A’ fastadhÌre 3
- City of Hope (Duarte), San Francisco
- UCSF Medical Center, San Francisco
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
A’ fastadhÌre 1/2
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
A’ fastadhÌre 2
- University of California, San Francisco, San Francisco
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
A’ fastadhÌre 2
- University of California San Francisco (UCSF), San Francisco
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
A’ fastadhÌre 2
- University of California San Francisco, San Francisco
Prospective Registry of ADC as First- and Second-line Treatment for Breast Cancer
A’ fastadhSgrùdadh amharcFàilte do shaor-thoilich fhallain
- University of California, San Francisco, San Francisco
A Study of NX-1607 in Adults With Advanced Malignancies
A’ fastadhÌre 1
- University of California, San Francisco, San Francisco
A Multicenter Cancer Biospecimen Collection Study
A’ fastadhSgrùdadh amharc
- Curebase, San Francisco
Sgrùdaidhean Cancer briste triple-negative ann am bailtean eile
- Houston, TX42 sgrùdaidhean
- New York City, NY31 sgrùdaidhean
- Nashville, TN28 sgrùdaidhean
- Los Angeles, CA27 sgrùdaidhean
- Boston, MA26 sgrùdaidhean
- San Antonio, TX23 sgrùdaidhean
- St. Louis, MO21 sgrùdaidhean
- Arlington, VA20 sgrùdaidhean
- Atlanta, GA20 sgrùdaidhean
- Dallas, TX18 sgrùdaidhean
- Chicago, IL16 sgrùdaidhean
- Columbus, OH16 sgrùdaidhean
Sgrùdaidhean eile ann an San Francisco
- Aillse Prostata45 sgrùdaidhean
- Aillse a' bhroilleach43 sgrùdaidhean
- Aillse Sgamhain Neo-chealla-beag36 sgrùdaidhean
- Aillse (gach seòrsa)35 sgrùdaidhean
- Fàilligeadh a' Chridhe29 sgrùdaidhean
- Ailse metastatach28 sgrùdaidhean
- Ailseachadh nan Sgamhan22 sgrùdaidhean
- Melanoma22 sgrùdaidhean
- Cancer Pancreatic20 sgrùdaidhean
- Cancer Ovarian19 sgrùdaidhean
- Aillse colorectal18 sgrùdaidhean
- Galarachd Cardiovasculach18 sgrùdaidhean
Bho ClinicalTrials.gov, dàta air a thogail 6 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.